Pangaea Data, AstraZeneca leverage AI to detect rare and hard-to-diagnose diseases
Pangaea Data, a company focused on detecting patients with hard-to-diagnose diseases, is collaborating with pharma giant AstraZeneca to scale AI that helps identify and connect patients to clinical trials and existing therapies.
“Today marks an important milestone for Pangaea Data as we begin a new multi-year collaboration with AstraZeneca, supported by Microsoft and NVIDIA, to bring multimodal, clinical-grade AI into everyday care at scale,” Vibhor Gupta, founder and CEO of Pangaea Data, told MobiHealthNews.
The partnership follows Pangaea’s announcement in June of a collaboration with Alexion, AstraZeneca’s rare-disease unit, to co-develop and clinically validate an AI-enabled tool for detecting hypophosphatasia in adults, with plans to seek regulatory approval.
London- and San Francisco-based Pangaea Data offers Pallux, a tool that uses AI and clinical guidelines to identify undertreated and undiagnosed patients.
Pangaea says it can detect diseases such as obstructive hypertrophic cardiomyopathy, Cushing’s syndrome, chronic kidney disease, systemic lupus erythematosus (SLE), chronic obstructive pulmonary disease (COPD) and others.
“Our aim is simple: to help clinicians close care gaps by identifying patients earlier and connecting them to the right treatments and clinical trials more effectively,” Gupta said.
Under the multi-year strategic agreement, AstraZeneca will sponsor the development, validation and deployment of Pangaea’s enterprise-grade platform that combines imaging, clinical, pathology, genomic and real‑world data using generative and predictive AI from Microsoft.
“By combining Pangaea’s clinical reasoning and patient-intelligence capabilities with Microsoft’s generative and predictive AI and NVIDIA’s accelerated compute, we can provide real-time, guideline-informed insights directly within existing clinical workflows,” Gupta said.
Pangaea announced in October that its platform capabilities would be combined with Microsoft Dragon Copilot, which provides real-time conversational analysis and recommendations generated from clinical interactions captured in real time.
Together, Pangaea and AstraZeneca will use AI to identify patients who are untreated, undertreated or misdiagnosed, as well as to generate cohorts for patient management.
The partners’ research teams will also train existing multimodal models to support point-of-care decisions and clinical trials.
The partnership will utilize Microsoft’s Azure AI infrastructure to power the training and deployment of the multimodal models, and Microsoft Fabric and confidential computing will be used for secure and compliant data sharing across global partners.
Through the collaboration, the pair also aim to identify patients in the EHR who may be in need of precision therapies, including evidence-based treatments and clinical trials.
“This collaboration reflects a shared commitment to responsible, secure and impactful AI application in healthcare,” Gupta said.
“I am proud of the work our teams have done to make it possible, and I’m very excited for what is to come in our work with AstraZeneca. I believe it represents a significant step toward more precise, equitable and sustainable care for patients around the world.”
